Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Analyst Joseph Pantginis commented,
Today’s announcement by REGN is an unfortunate event that refocuses its efforts on eye disease to the aflibercept/nesvacumab combination therapy. However it continues to point to Eylea's continued strong efficacy as a monotherapy. At the present Regeneron and Bayer (BAYN-NC) are jointly developing and evaluating the combination therapy and it is currently in two Phase II clinical trials for intravitreal injection in patients with wet age-related macular degeneration and diabetic macular edema.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron (REGN): Dermatology Survey Confirms Bullish Outlook - Leerink
- AK Steel (AKS) PT, Estimates Raised at Jefferies
- Apple (AAPL) PT Raised to $135 at Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!